Please login to the form below

Not currently logged in

Three cancer immunotherapies amongst new CHMP approvals

BMS’ Evotaz also amongst eight new medicine recommendations

EU flag 

Keytruda, Nivolumab and Unituxin are amongst eight new medicines recommended for approval at this month's meeting of the Committee for Medicinal Products for Human Use (CHMP).

Merck's Keytruda (pembrolizumab) has been granted positive opinion to treat advanced melanoma, news that will further please the company following a head-to-head trial with BMS' Yervoy where it outperformed the world's biggest selling melanoma drug.

Nivolumab BMS (nivolumab) received positive opinion to treat adults with squamous non-small lung cancer (NSCLC), while Unituxin (dinutiximab) was given the nod for the treatment of high-risk neuroblastoma, a cancer that is most common in young children.

Further recommendations

Away from immunotherapies, the Committee gave marketing authorisation for Repatha (evolocumab), a first-in-class treatment to lower high levels of cholesterol in the blood of patients where statins are ineffective or who cannot take statins.

Repatha is the first monoclonal antibody in this therapeutic area and is additionally recommended to treat homozygous familial hypercholesterolaemia, a rare inherited disease.

The CHMP also recommended BMS' Evotaz (atazanavir/cobicistat) for HIV-1 infected adults without known mutations associated with resistance to atazanavir, further good news for the company following the FDA's approval for the same indication earlier this year.

Omidria (phenylephrine/ketorolac) received a positive opinion from the Committee for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.

Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised anxiety disorder.

Article by
Kirstie Pickering

27th May 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...